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Purpose: We assessed the role of monocarboxylate transporter 1 (MCT1) on lactate clearance 2 
during an active recovery after high intensity exercise, by comparing genetic groups based on the 3 
T1470A (rs1049434) MCT1 polymorphism, whose influence on lactate transport has been proven. 4 
Methods: Sixteen young male elite field hockey players participated in this study. All of them 5 
completed two 400 m maximal run tests performed on different days, followed by 40 min of active 6 
or passive recovery. Lactate samples were measured immediately after the tests, and at min 10, 20, 7 
30 and 40 of the recoveries. Blood lactate decreases were calculated for each 10 min period. 8 
Participants were distributed into three groups according to the T1470A polymorphism (TT, TA 9 
and AA). Results: TT group had a lower blood lactate decrease than AA group during the 10-20 10 
min period of the active recovery (p=0.018). This period had the highest blood lactate for the 11 
whole sample, significantly differing from the other periods (p≤0.003). During the passive 12 
recovery, lactate declines were constant except for the 0-10 min period (p≤0.003), suggesting that 13 
liver uptake is similar in all the genetic groups, and that the difference seen during the active 14 
recovery is mainly due to muscle lactate uptake. Conclusions: These differences according to the 15 
polymorphic variant T1470A suggest that MCT1 plays a central role in taking up lactate from the 16 
plasma to the muscle affects the plasma lactate decrease during a crucial period of active recovery, 17 
where the maximal lactate amount is cleared (i.e. 10-20 min period). 18 
 19 
Keywords: Monocarboxylate transporters, lactate clearance, active recovery. 20 
 21 
Abbreviations: DNA: Deoxyribonucleic acid; MCT: Monocarboxylate transporter; PCR: 22 






































































During exercise, oxidation by muscle and heart and gluconeogenesis by the liver 2 
are the main fates for lactate (Bergman et al. 1999). Particularly, the oxidative 3 
skeletal muscle contracting at submaximal intensity is the principal consumer 4 
(Gladden 2004). This fact is reflected during low or moderate-intensity active 5 
recovery, which has been proven to be efficient; increasing the blood lactate 6 
clearance after high intensity exercise, especially during the first 20 min. (Baker 7 
and King 1991; Baldari et al. 2004; Menzies et al. 2010; Micklewright et al. 8 
2006). Most of the membrane lactate transport (in symport with a proton) occurs 9 
via a monocarboxylate transporter (MCT), with the MCT1 being the predominant 10 
isoform in muscles (Fishbein et al. 2002; Pilegaard et al. 1999). The relevance of 11 
MCT1 after high intensity exercise has already been reported by previous studies, 12 
which found an association between MCT1 content and blood lactate removal or 13 
blood lactate concentration (Green et al. 2002; Thomas et al. 2005). However, 14 
these investigations used a passive recovery protocol, with a lower requirement 15 
over MCT1 because resting muscles take less lactate due to a lower metabolic rate 16 
(Brooks 2009; Gladden 2008; Miller et al. 2002). On the contrary, it would be 17 
more relevant to investigate MCT1 and lactate clearance during active recovery, 18 
in which lactate uptake by the muscles is increased (Miller et al. 2002). Moreover, 19 
this type of recovery is a common situation during some training protocols, such 20 
as high intensity interval training protocols, and during some sports, such as 21 
intermittent team sports (Macutkiewicz and Sunderland 2011). Therefore, MCT1 22 
is expected to have a relative importance during active recovery after high 23 
intensity exercise. However, we do not know if its implication is constant over the 24 



































































The T1470A (rs1049434) polymorphism in the MCT1 gene (SLC16A1) is a 1 
single-nucleotide polymorphism (SNP) (Lean and Lee 2009; Merezhinskaya et al. 2 
2000) that has been related with sports performance and lactate transport (Ben-3 
Zaken et al. 2015; Cupeiro et al. 2010; Cupeiro et al. 2012; Fedotovskaya et al. 4 
2014; Sawczuk et al. 2015), suggesting an impaired lactate transport in men 5 
carrying the T allele. This reduced lactate transport associated with the SLC16A1 6 
1470T allele has recently been confirmed by Sasaki et al., who found a lower 7 
lactate uptake in oocytes expressing the wild type protein (i.e. the T allele) (Sasaki 8 
et al. 2015). Thus, by comparing blood lactate concentrations of the different 9 
genotype groups (TT, TA, AA) we aimed to assess the role of the MCT1 in blood 10 
lactate clearance during an active recovery, proposing that a meaningful 11 
involvement of MCT1 would be reflected on different lactate levels among 12 
genetic groups. 13 
We hypothesize that the main involvement of MCT1 occurs during the period of 14 
maximal lactate clearance of the active recovery, that is, the first 20 minute-15 
period. In our study we investigated the role of the MCT1 on lactate removal 16 
dynamics during an active recovery, using the T1470A (rs1049434) MCT1 17 
genetic variant as a determinant of different functionality. Regarding the genotype 18 
comparison of MCT1 isoforms, we hypothesize that the AA group has a greater 19 
blood lactate clearance than the TT and TA groups during the active recovery, 20 
while the three groups will have the same blood lactate decrease during the 21 





































































Sixteen healthy male field hockey players (age 21.7 ± 2.7 years, height 1.74 ± 3 
0.06 m, body mass 70.0 ± 6.3 kg) of the same team competing in the highest 4 
Spanish national level league participated in this study. We tested this sample 5 
because it allowed an extensive control of diet and training. During the two years 6 
prior to the data collection, these two factors were standardized and controlled. 7 
Furthermore, all of the subjects were of the same Spanish (Caucasian) ancestry for 8 
at least three generations. All principles outlined in the Declaration of Helsinki 9 
were strictly followed. The design and performance of the research study was 10 
described in the research protocol at the beginning of the study. All participants 11 
signed an informed consent which includes: 1) the goal of the study; 2) a 12 
statement for the unique use of the samples for the current study; and 3) explicit 13 
anonymity about the final genetic result. The study was presented and approved 14 
by an Academic Review board in the Department of Medical Sciences at the 15 
University of Cantabria. 16 
Experimental procedure 17 
Participants performed two 400 m maximal run tests on a standard 400 m track, 18 
each test followed by 40 min of an active or passive recovery, in the first and 19 
second day, respectively. The active recovery involved 40 min of running at a 20 
self-regulated intensity, which has proved to be suitable for lactate clearance 21 
(Bonen and Belcastro 1976; Menzies et al. 2010). Subsequent analysis revealed 22 
that this self-regulated intensity corresponded to 65%-75% of their age-predicted 23 
maximal heart rate (Tanaka et al. 2001). The passive recovery consisted of sitting 24 



































































the tests, which were separated by at least one recovery day. The experimental 1 
protocol was double blinded in the sense that neither the evaluators nor the 2 
subjects knew the genotype during the study. 3 
Lactate, heart rate and anthropometric measurements 4 
For measuring capillary lactate concentrations, blood samples from the fingertip 5 
were obtained at rest before the 400 m run tests, immediately after finishing them 6 
and four times during the recoveries: at min 10, 20, 30 and 40. These samples 7 
were analyzed immediately after they were drawn using the Accusport portable 8 
blood lactate analyzer (Boehringer Mannheim, Manheim, Germany), which has 9 
been found to be valid and reliable (Bishop 2001; Pinnington and Dawson 2001). 10 
Furthermore, only one device was used for all the measurements in order to avoid 11 
potential error due to the use of different analyzers (Bishop 2001; Pinnington and 12 
Dawson 2001). 13 
Heart rate was recorded during all the trials and recoveries using a HR monitor 14 
(Polar Electro, Kempele, Finland). Anthropometric measurements included height 15 
and body mass using a balance with height attachment (Model 713, SECA, 16 
Hamburg, Germany). 17 
Genotype assessment 18 
For the genetic analysis genomic DNA was extracted from peripheral blood using 19 
a QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany). Genomic DNAs 20 
from the participants were analyzed by polymerase chain reaction (PCR) 21 
amplification of a fragment containing the T1470A polymorphism of the MCT1 22 
gene (rs1049434, exon 5) and following direct sequencing. According with 23 



































































were as follows: sense primer 5’-ACA CAT ACT GGG CAT GTG GC-3’ (1455–1 
1474); antisense primer 5’-AAA TCC CAT CAA TGA ACA ACT GGT ATG 2 
ATT TCC AC-3’ (1807–1841). PCR reaction was made in a total volume of 50 3 
L containing: 3 L genomic DNA, 1.5 mM MgCl2, 0.2 mM dNTP mix, 0.4 M 4 
primer, 4% dimethyl sulfoxide (SIGMA, Sant Louis, MO, USA) and 1U Taq 5 
polymerase (BioTaqPolimerase, Bio- Line, London, UK), using a GeneAmp® 6 
PCR System 2400 thermal cycler (Perkin Elmer, Applied Biosystems Division, 7 
Foster City, CA, USA). The amplification consisted of initial denaturation (94 ºC, 8 
5 min); 35 cycles consisting of denaturation (94 ºC, 1 min), annealing (55 ºC, 1 9 
min), and extension (72 ºC, 1 min); and final extension (72 ºC, 10 min). PCR 10 
products were electrophoresed in 1.5% agarose gel to verify successful 11 
amplification of the 387 bp fragments. Prior to sequencing, the PCR products 12 
were purified using QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). 13 
The sequencing reactions were carried out using dRhodamine Terminator Cycle 14 
Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and analyzed on the 15 
automated ABI Prism 310 Genetic Analyzer (Applied Biosystems). Gene 16 
sequence of exon 5 was obtained from GeneBank (Accession: NM 003051). 17 
Data Analysis 18 
To analyze blood lactate clearance, we divided the 40 min recoveries into four 19 
phases of 10 min. Lactate removal during each 10 min period was calculated by 20 
subtracting the blood lactate concentration at the beginning of the phase from the 21 
blood lactate concentration measured at the end of the phase. This calculation 22 
reflected the blood lactate decrease in each defined period. 23 
The statistical analysis was performed using the Statistical Package for the Social 24 



































































significance was set at 0.05. To determine the normal distribution of the variables 1 
we used a Shapiro-Wilk test and the Chi-square test was conducted to evaluate the 2 
Hardy-Weinberg equilibrium. Given the sample size and the variables 3 
distribution, non-parametric tests were used. 4 
To assure both 400 m tests (active recovery test and passive recovery test) were 5 
equally executed, in terms of performance and maximal effort and were different 6 
in terms of recovery, a Wilcoxon test with Holm adjustment for multiple 7 
comparisons was carried out with the entire sample and within each genotype 8 
group. The variables for this analysis were time to complete the trials, heart rate 9 
values and lactate concentrations measured throughout the tests, as well as the 10 
lactate reductions during each 10 min phase of the recovery. Furthermore, 11 
Friedman tests followed by Wilcoxon tests were used to compare the lactate 12 
removed during the different 10 min phases within each recovery. On the other 13 
hand, a Kruskal-Wallis test was used to compare anthropometric parameters and 14 
age across genotypes, and to guarantee the equal performance of the tests among 15 
genetic groups. Finally, we used a Friedman test to analyze differences in lactate 16 
clearance phases across genetic groups. Data are presented as mean and standard 17 
deviation (SD). 18 
RESULTS 19 
We did not experience any failure in the sample collection, DNA acquisition or 20 
genotyping procedures. Genotype frequencies were 4 (25.0%), 6 (37.5%), and 6 21 
(37.5%) for the TT, TA and AA genotypes respectively, being in accordance with 22 



































































The Wilcoxon test comparing the two 400 m maximal run tests showed no 1 
differences in time trial, maximal heart rate reached, basal lactate and lactate 2 
concentration immediately after the test (Table 1). These parameters were also 3 
similar among genetic groups, as well as the intensity of the active recovery 4 
expressed by the percentage of their age-predicted maximal heart rate (data not 5 
shown). We observed differences between active and passive recoveries in all the 6 
lactate measurements (Table 1) and in all 10 min intervals (p≤0.007), except for 7 
the 20-30 min period. Within the passive recovery the rate of lactate removal was 8 
constant over the 40 min except for the first 10 min (p≤0.003), since blood lactate 9 
did not decrease during this period. On the other hand, during the active recovery 10 
the highest decrease of blood lactate appeared in the 10-20 min period (5.6 ± 1.1 11 
mM/L). This decrease significantly differed from the others (p≤0.003), whereas 12 
the lactate reduction for the 0-10 min period (1.6 ± 2.3mM/L) was similar to those 13 
in the 20-30 (2.0 ± 1.3mM/L) and 30-40 min periods (0.4 ± 0.5mM/L). 14 
 15 
Table 1 about here 16 
 17 
No differences were observed for anthropometric values or age across genotypes 18 
(Table 2). Comparison of lactate concentrations among groups revealed no 19 
differences, but the analysis of the lactate decreases reported a difference between 20 
TT and AA groups in the 10-20 min period (Figure 1). During this phase (i.e. the 21 
one with the maximum decrease of blood lactate) AA group exhibited a higher 22 
lactate decrease than TT group. On the other hand, no differences were observed 23 



































































Table 2 about here 1 
 2 
Figure 1 about here 3 
 4 
DISCUSSION 5 
Our main finding was the greater lactate reduction observed in the AA group 6 
compared to TT group during the 10-20 min period of the active recovery, which 7 
had the highest lactate clearance compared to the rest of the recovery periods 8 
(active or passive). These results suggest a higher participation of MCT1 during 9 
this period, reflecting the key role of MCT1 on high lactate transport rates. 10 
The allele frequencies observed in our sample were similar to those seen in 11 
previous studies with non-sedentary subjects (Ben-Zaken et al. 2015; Cupeiro et 12 
al. 2010; Cupeiro et al. 2012; Sawczuk et al. 2015). An allelic frequency of 30%-13 
35% for the T allele is commonly observed, especially in non-athletic populations 14 
(Ben-Zaken et al. 2015; Merezhinskaya et al. 2000; Lean and Lee 2009; Sawczuk 15 
et al. 2015). However, within athletic samples, the frequencies vary widely, 16 
depending on the sport they perform (Fedotovskaya et al. 2014; González-Haro et 17 
al. 2015; Sawczuk et al. 2015). These differences could be due to a sport 18 
specialization (Ben-Zaken et al. 2015; Fedotovskaya et al. 2014; Sawczuk et al. 19 
2015) or to an adaptive process of natural selection in populations and the neutral 20 
processes of genetic drift in populations of different origin. Therefore, further 21 



































































We observed a difference in blood lactate removal between genotypes according 1 
to the T1470A MCT1 polymorphism, which alters lactate movement through this 2 
transporter (Sasaki et al. 2015), only during the active recovery. Lactate uptake by 3 
different organs involves both the MCT and the less efficient process of diffusion 4 
(important at concentration >2 mM/L), thus it must be discussed if the 5 
encountered differences could be due to the uptake by other organs, such as the 6 
liver, expressing other MCT isoforms (Gladden 2008). Lactate removal by the 7 
liver accounts for approximately 30% of total removal in resting humans 8 
(Gladden, 2008) and no significant changes are reported after 40 min of low-9 
intensity exercise (Ahlborg, 1974). Consequently, we can assume that the role of 10 
liver in active and passive recovery is similar. Therefore, the lack of differences 11 
during the passive recovery among genetic groups implies that liver function is 12 
similar in all the three groups, and that the difference we found is not due to liver 13 
function but to muscle lactate uptake (i.e. the only condition that varies between 14 
active and passive recoveries). Furthermore, this difference was only observed 15 
from minute 10 to 20 of the recovery, suggesting that the transporter is especially 16 
relevant during that period, where previous studies (Baker and King 1991; 17 
Micklewright et al. 2006), as well as our results, locate the maximum rate of 18 
blood lactate clearance. These results, alongside the fact that MCT1 is the 19 
predominant isoform in oxidative skeletal fibers (Fishbein et al. 2002) and in 20 
cardiac muscle (Gladden 2008), suggest that this transporter plays a central role in 21 
taking up lactate from the plasma to the muscle exhibiting differences according 22 
to the polymorphic variant T1470A. On the other hand, we did not find 23 
differences in the other recovery periods (i.e. min 0-10, 20-30 and 30-40) maybe 24 
because the reported blood lactate concentrations did not reach a minimal 25 



































































previously hypothesized (Cupeiro et al. 2010; Cupeiro et al. 2012). Furthermore, 1 
the first 10 min of the recovery, where lactate concentrations still remain high, 2 
seems to be an adjustment phase where the blood lactate concentration depends on 3 
multiple factors, including blood redistribution, buffer capacity or lactate efflux 4 
from glycolytic fibers (Oyono-Enguelle et al. 1990). 5 
Although these results should be taken with caution, since we did not evaluate 6 
other factors influencing lactate removal (e.g. like mitochondrial oxidative 7 
capacity or fiber type composition), our data suggests a key role of MCT1 in 8 
lactate transport; especially during active recovery, when muscles are exercising 9 
at low intensity and type I fibers are the most involved. Under these conditions, 10 
MCT1 efficiency should be crucial, since a higher lactate transport would 11 
increment the chance to use this metabolite as a substrate and an elevated proton 12 
efflux from the muscle could prevent fatigue due to the proton gradient from 13 
lactate producers to lactate consumers. Furthermore, we tried to limit the effect of 14 
other factors on lactate removal selecting a very homogeneous sample in terms of 15 
age, body composition and physical capacity, and controlling and standardizing 16 
their training regime over two years. 17 
Our data reflects significant differences in blood lactate clearance on subjects with 18 
different efficiencies of MCT1 (i.e. AA and TT groups), observing a more 19 
effective lactate take up in the AA genotype group. Trainers should consider this 20 
fact for designing personalized recovery timings, both during training and 21 
competition. Raising the efficiency of MCT1 must be a molecular target, in order 22 
to modulate lactate and proton transport during recovery or low/moderate 23 
intensity phases of competition; and therefore, not only improving energy 24 



































































the knowledge about the role of MCT1 during recovery are needed, especially for 1 
analyzing the involvement of the transporter in women, varying the intensity of 2 
the recovery, during intermittent exercise or high intensity interval training. 3 
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Figure 1. Rates of lactate clearance during the active recovery by genotype groups. * Significant 1 



































































Table 1. Performance variables in both 400 m maximal run tests and lactate concentrations during 1 
active and passive recoveries 2 
 Active recovery test Passive recovery test p 
Time (s) 65.32 (4.13) 65.22 (4.05) 0.925 
Heart Rate at the end of the 400 
m run (bpm) 
1865.87 (87.86) 1843.71 (87.67) 0.454 
Basal blood lactate (mM/L) 1.4 (0.4) 1.4 (0.3) 0.975 
Blood lactate at the end of the 
400 m run (mM/L) 
11.2 (2.5) 11.0 (2.2) 0.552 
Blood lactate 10 min after the 
end of the 400 m run (mM/L) 
9.6 (2.0) 12.5 (1.7) 0.005 
Blood lactate 20 min after the 
end of the 400 m run (mM/L) 
4.0 (1.7) 9.7 (1.6) <0.001 
Blood lactate 30 min after the 
end of the 400 m run (mM/L) 
2.1 (0.7) 6.7 (2.4) <0.001 
Blood lactate 40 min after the 
end of the 400 m run (mM/L) 
1.7 (0.5) 4.9 (1.4) <0.001 






































































Table 2. Descriptive variables for the genotype groups. 2 
 TT (n=4) TA (n=6) AA (n=6) p 
Age (years) 21.5 (4.0) 20.8 (1.2) 22.7 (3.0) 0.612 
Height (cm) 173.5 (3.7) 175.4 (8.2) 173.7 (5.2) 0.963 
Weight (kg) 69.0 (2.0) 72.0 (9.9) 68.7 (3.1) 0.998 
Values are presented as mean (SD). There were no statistical differences 



































































































Figure Click here to download Figure Fig1.eps 
